RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Australia: Draft Guidance on Evidence to Support Indications for Low Risk Medicines

Australia: Draft Guidance on Evidence to Support Indications for Low Risk Medicines

Posted 24 April 2012 | By Louise Zornoza

Australia's Therapeutic Goods Administration (TGA) is seeking comment from interested parties on draft guidance Evidence Required to Support Indications for Listed Medicines (excluding sunscreens and disinfectants).

The draft specifies the type of evidence required to support indications made for listed (low risk) medicines (including weight loss products) and is intended to replace the Guidelines for Levels and Kinds of Evidence to Support Indications and Claims for Non-Registerable Medicines, including Complementary Medicines and other Listable Medicines.


Read more:

TGA - Evidence Required to Support Indications for Listed Medicines (excluding sunscreens and disinfectants)

TGA - Guidelines for Levels and Kinds of Evidence to Support Indications and Claims for Non-Registerable Medicines, including Complementary Medicines and other Listable Medicines

More Breaking News from RegLink

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe